Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02586415
Recruitment Status : Terminated (Interim analysis showed a high likelihood of benefit in the endovascular group)
First Posted : October 26, 2015
Results First Posted : September 19, 2018
Last Update Posted : May 21, 2019
Sponsor:
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
University of Cincinnati
Medical University of South Carolina
NINDS Stroke Trials Network (StrokeNet)
Information provided by (Responsible Party):
Gregory W Albers, Stanford University

Tracking Information
First Submitted Date  ICMJE October 21, 2015
First Posted Date  ICMJE October 26, 2015
Results First Submitted Date  ICMJE August 23, 2018
Results First Posted Date  ICMJE September 19, 2018
Last Update Posted Date May 21, 2019
Study Start Date  ICMJE April 2016
Actual Primary Completion Date August 23, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 23, 2018)
The Distribution of Scores on the Modified Rankin Scale (mRS) at Day 90 [ Time Frame: Day 90 ]
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. 0 - No symptoms.
  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
  3. - Moderate disability. Requires some help, but able to walk unassisted.
  4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
  5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
  6. - Dead.
Original Primary Outcome Measures  ICMJE
 (submitted: October 22, 2015)
The distribution of scores on the modified Rankin Scale (mRS) at day 90 [ Time Frame: 90 days ]
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. 0 - No symptoms.
  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
  3. - Moderate disability. Requires some help, but able to walk unassisted.
  4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
  5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
  6. - Dead.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2018)
Count of Patients With mRS 0-2 at Day 90 as a Measure of Functional Independence [ Time Frame: day 90 ]
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. 0 - No symptoms.
  • No significant disability. Able to carry out all usual activities, despite some symptoms.
  • Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
  • Moderate disability. Requires some help, but able to walk unassisted.
  • Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
  • Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
  • Dead.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 22, 2015)
proportion of patients with mR S 0-2 [ Time Frame: 90 days ]
This outcome will look at the proportion of patients with mR S 0-2 at day 90 (indicating functional independence). The difference in the proportions of patients with mRS 0-2 between treatment arms will be assessed using logistic regression.
Current Other Pre-specified Outcome Measures
 (submitted: May 13, 2019)
  • Count of Participants With Symptomatic Intracranial Hemorrhage (Primary Safety Outcome) [ Time Frame: 36 hours ]
    Defined as NIHSS worsening of 4 or more points associated with brain hemorrhage within 36 hours of randomization
  • Parenchymal Hematoma Type 2 (Safety Outcome) [ Time Frame: 24 (±6) hours ]
    PH 2 rates on the 24 hour scan (±6)
  • Infarct Volume (Imaging Outcome) [ Time Frame: 24 (+/- 6) hours ]
    Infarct volume on diffusion-weighted MRI (or CT if MRI not feasible) at 24 (±6) hours after randomization
  • Lesion Growth (Imaging Outcome) [ Time Frame: 24 hours (±6) ]
    Lesion growth between the RAPID-identified ischemic core on baseline imaging and the infarct volume at 24 hours (±6)
  • Reperfusion (Imaging Outcome) [ Time Frame: between baseline and 24 hours (+/- 6 hours) ]
    Successful reperfusion defined as a >90% reduction in Tmax>6sec lesion volume between baseline and 24 hours
  • Recanalization (Imaging Outcome) [ Time Frame: 24 hours (±6) ]
    Recanalization of the primary arterial occlusive lesion at 24-hours on CTA/MRA
Original Other Pre-specified Outcome Measures
 (submitted: October 22, 2015)
Infarct growth [ Time Frame: 24 hours ]
Infarct volumes, ischemic lesion growth, and reperfusion rates at 24 hours will be compared between groups
 
Descriptive Information
Brief Title  ICMJE Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Official Title  ICMJE Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Brief Summary This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.
Detailed Description

DEFUSE 3 is a prospective randomized Phase III multicenter controlled trial of patients with acute ischemic anterior circulation strokes due to large artery occlusion treated between 6-16 hours of stroke onset with endovascular thrombectomy therapy vs. control.

The primary endpoint, the modified Rankin Score, will be assessed at 3 months. The patients' participation in the study concludes at that time (3 months from stroke onset). The study will randomize up to 476 patients over 4 years. The purpose of DEFUSE 3 is to assess the safety and efficacy of thrombectomy in carefully selected patients in an extended time window. Only the devices listed in this protocol will be used. Selection of the specific device (or devices) is determined by the individual endovascular therapist.

Patients who meet the inclusion criteria will undergo either CT Perfusion/CT Angiogram or MR DWI/PWI/MRA studies prior to randomization. Patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile will be randomized in a 1:1 ratio to treatment with one or more DEFUSE 3 approved thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy versus standard medical therapy alone. Patients who are enrolled, but not randomized, will receive standard therapy according to local guidelines. Baseline data, and information about early stroke therapies, will be captured for this group of patients.

Randomization of a maximum of 476 patients is planned. A novel adaptive design will identify, at interim analyses, the group with the best prospect for showing benefit from endovascular treatment, based on baseline core lesion volumes and the times since stroke onset. Interim analyses will be conducted at 200 and 340 patients, at which time the study may stop for efficacy/futility, or the inclusion criteria may be adjusted in the case of futility.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Stroke, Acute
  • Cerebral Infarction
Intervention  ICMJE
  • Procedure: Endovascular Thrombectomy
    Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
  • Device: Trevo Retriever
    Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
  • Device: Solitaire™ FR Revascularization Device
    Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
  • Device: Penumbra thrombectomy system

    Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:

    • Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68

  • Device: Covidien MindFrame Capture Revascularization Device
    Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
Study Arms  ICMJE
  • Active Comparator: endovascular thrombectomy therapy

    Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.

    Devices approved for use in DEFUSE 3:

    • Trevo Retriever
    • Solitaire™ FR Revascularization Device
    • Penumbra thrombectomy system
    • Covidien MindFrame Capture Revascularization Device
    Interventions:
    • Procedure: Endovascular Thrombectomy
    • Device: Trevo Retriever
    • Device: Solitaire™ FR Revascularization Device
    • Device: Penumbra thrombectomy system
    • Device: Covidien MindFrame Capture Revascularization Device
  • No Intervention: Medical Management
    standard medical therapy alone
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 4, 2017)
182
Original Estimated Enrollment  ICMJE
 (submitted: October 22, 2015)
476
Actual Study Completion Date  ICMJE August 23, 2017
Actual Primary Completion Date August 23, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Clinical Inclusion Criteria:

  1. Signs & symptoms consistent w/ the diagnosis of acute anterior circulation ischemic stroke
  2. Age 18-90 years
  3. Baseline NIHSSS is ≥ 6 and remains ≥6 immediately prior to randomization
  4. Endovascular treatment can be initiated (femoral puncture) between 6 and 16 hours of stroke onset. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline (wake-up strokes are eligible if they meet the above time limits).
  5. modified Rankin Scale less than or equal to 2 prior to qualifying stroke (functionally independent for all ADLs)
  6. Patient/Legally Authorized Representative has signed the Informed Consent form.

Clinical Exclusion Criteria:

  1. Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 6 months.
  2. Pre-existing medical, neurological or psychiatric disease that would confound the neurological or functional evaluations
  3. Pregnant
  4. Unable to undergo a contrast brain perfusion scan with either MRI or CT
  5. Known allergy to iodine that precludes an endovascular procedure
  6. Treated with tPA >4.5 hours after time last known well
  7. Treated with tPA 3-4.5 hours after last known well AND any of the following; age >80, current anticoagulant use, history of diabetes or prior stroke, NIHSS >25
  8. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 3 (recent use of one of the new oral anticoagulants is not an exclusion if estimated GFR > 30 ml/min).
  9. Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS
  10. Baseline blood glucose of <50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol)
  11. Baseline platelet count < 50,000/uL
  12. Severe, sustained hypertension (Systolic BP >185 mmHg or Diastolic BP >110 mmHg)
  13. Current participation in another investigational drug or device study
  14. Presumed septic embolus; suspicion of bacterial endocarditis
  15. Clot retrieval attempted using a neurothrombectomy device prior to 6 hrs from symptom onset
  16. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.

Neuroimaging Inclusion Criteria:

  1. ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions) by MRA or CTA

    AND

  2. Target Mismatch Profile on CT perfusion or MRI (ischemic core volume is < 70 ml, mismatch ratio is >/= 1.8 and mismatch volume* is >/= 15 ml)

Alternative neuroimaging inclusion criteria (if perfusion imaging or CTA/MRA is technically inadequate):

A) If CTA (or MRA) is technically inadequate:

Tmax>6s perfusion deficit consistent with an ICA or MCA-M1 occlusion AND Target Mismatch Profile (ischemic core volume is < 70 ml, mismatch ratio is >1.8 and mismatch volume is >15 ml as determined by RAPID software)

B) If MRP is technically inadequate:

ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions) by MRA (or CTA, if MRA is technically inadequate and a CTA was performed within 60 minutes prior to the MRI) AND DWI lesion volume < 25 ml

C) If CTP is technically inadequate:

Patient can be screened with MRI and randomized if neuroimaging criteria are met.

Neuroimaging Exclusion Criteria:

  1. ASPECTS score <6 on non-contrast CT (if patient is enrolled based on CT perfusion criteria)
  2. Evidence of intracranial tumor (except small meningioma) acute intracranial hemorrhage, neoplasm, or arteriovenous malformation
  3. Significant mass effect with midline shift
  4. Evidence of internal carotid artery dissection that is flow limiting or aortic dissection
  5. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device
  6. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02586415
Other Study ID Numbers  ICMJE 116661
U10NS086487 ( U.S. NIH Grant/Contract )
U01NS092076 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Gregory W Albers, Stanford University
Study Sponsor  ICMJE Gregory W Albers
Collaborators  ICMJE
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of Cincinnati
  • Medical University of South Carolina
  • NINDS Stroke Trials Network (StrokeNet)
Investigators  ICMJE
Principal Investigator: Gregory Albers, MD Stanford University
Principal Investigator: Michael Marks, MD Stanford University
Principal Investigator: Maarten Lansberg, MD, PhD Stanford University
PRS Account Stanford University
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP